Submit details of adverse events reported: CDSCO Panel Tells GSK on Mepolizumab Powder for Solution for Injection Dr. Divya Colin24 Aug 2024 6:00 PM ISTNew Delhi: In line with the Phase IV clinical trial report of the monoclonal antibody Mepolizumab (Brand Name: Nucala 100 mg) presented by the drug...
AstraZeneca Fasenra approved in China for severe eosinophilic asthma Ruchika Sharma23 Aug 2024 4:05 PM ISTCambridge: AstraZeneca's Fasenra (benralizumab) has been approved in China by the country's National Medical Products Association (NMPA) for the...
GSK Nucala approved in China for use in severe asthma with eosinophilic phenotype Ruchika Sharma12 Jan 2024 11:35 AM ISTLondon: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), as an add-on...
Mepolizumab Shows Promising Treatment of Severe Eosinophilic Asthma Jacinthlyn Sylvia28 July 2023 9:30 AM ISTIn a recent multicenter study, Giulia Scioscia and peers found that in patients with severe eosinophilic asthma switching from mepolizumab to...
Dexpramipexole safe and efficacious option for Patients With Eosinophilic Asthma Dr. Shravani Dali24 July 2023 9:15 AM ISTDexpramipexole safe and efficacious option for Patients With Eosinophilic Asthma suggests a new study published in the Journal of Allergy and Clinical...
Pros of Switching from omalizumab or mepolizumab to Benralizumab in asthma patients Isra Zaman1 Jun 2022 10:30 AM ISTPatients diagnosed with severe refractory eosinophilic asthma who experience a partial response with omalizumab or mepolizumab could benefit from...
